Compounds > losartan-potassium

losartan-potassium and Telangiectasis

losartan-potassium has been researched along with Telangiectasis* in 4 studies

Other Studies

4 other study(ies) available for losartan-potassium and Telangiectasis

ArticleYear
The TEMPI syndrome.
    Blood, 2020, 04-09, Volume: 135, Issue:15

    The TEMPI syndrome is a rare and acquired disorder characterized by 5 salient features, which compose its name: (1) telangiectasias; (2) elevated erythropoietin and erythrocytosis; (3) monoclonal gammopathy; (4) perinephric fluid collections; and (5) intrapulmonary shunting. Complete resolution of symptoms following treatment with plasma cell-directed therapy supports the hypothesis that the monoclonal antibody is causal and pathogenic. Understanding the basis of the TEMPI syndrome will depend on the identification of additional patients and a coordinated international effort.

    Topics: Erythropoietin; Humans; Lung Diseases; Paraproteinemias; Polycythemia; Syndrome; Telangiectasis

2020
Bortezomib to treat the TEMPI syndrome.
    The New England journal of medicine, 2012, May-10, Volume: 366, Issue:19

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Lymphangiectasis; Middle Aged; Paraproteinemias; Polycythemia; Pyrazines; Syndrome; Telangiectasis

2012
Complete and partial responses of the TEMPI syndrome to bortezomib.
    The New England journal of medicine, 2012, Aug-23, Volume: 367, Issue:8

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Male; Middle Aged; Paraproteinemias; Polycythemia; Pyrazines; Syndrome; Telangiectasis

2012
The TEMPI syndrome--a novel multisystem disease.
    The New England journal of medicine, 2011, Aug-04, Volume: 365, Issue:5

    Topics: Adult; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Hydronephrosis; Lymphangiectasis; Male; Middle Aged; Paraproteinemias; Polycythemia; Protease Inhibitors; Pyrazines; Syndrome; Telangiectasis

2011